[
Angiogenesis
Ovarian cancer
PET imaging
Pazopanib
Platinum resistance
[18F]Fluciclatide
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
14
05
2019
accepted:
11
09
2019
pubmed:
23
11
2019
medline:
15
5
2021
entrez:
23
11
2019
Statut:
ppublish
Résumé
Angiogenesis is a driver of platinum resistance in ovarian cancer. We assessed the effect of combination pazopanib and paclitaxel followed by maintenance pazopanib in patients with platinum-resistant/refractory ovarian cancer. Integrins α We conducted an open-label, phase Ib study in patients with platinum-resistant/refractory ovarian cancer. Patients received 1 week of single-agent pazopanib (800 mg daily) followed by combination therapy with weekly paclitaxel (80 mg/m Fourteen patients were included in the intention-to-treat analysis. Complete and partial responses were seen in seven patients (54%). Median progression-free survival (PFS) was 10.63 months, and overall survival (OS) was 18.5 months. Baseline [ Combination therapy followed by maintenance pazopanib is effective and tolerable in platinum-resistant/refractory ovarian cancer. [
Sections du résumé
BACKGROUND
Angiogenesis is a driver of platinum resistance in ovarian cancer. We assessed the effect of combination pazopanib and paclitaxel followed by maintenance pazopanib in patients with platinum-resistant/refractory ovarian cancer. Integrins α
PATIENTS AND METHODS
We conducted an open-label, phase Ib study in patients with platinum-resistant/refractory ovarian cancer. Patients received 1 week of single-agent pazopanib (800 mg daily) followed by combination therapy with weekly paclitaxel (80 mg/m
RESULTS
Fourteen patients were included in the intention-to-treat analysis. Complete and partial responses were seen in seven patients (54%). Median progression-free survival (PFS) was 10.63 months, and overall survival (OS) was 18.5 months. Baseline [
CONCLUSIONS
Combination therapy followed by maintenance pazopanib is effective and tolerable in platinum-resistant/refractory ovarian cancer. [
Identifiants
pubmed: 31754793
doi: 10.1007/s00259-019-04532-z
pii: 10.1007/s00259-019-04532-z
pmc: PMC7101300
doi:
Substances chimiques
AH 111585
0
Biomarkers
0
Indazoles
0
Peptides
0
Pyrimidines
0
Sulfonamides
0
Polyethylene Glycols
3WJQ0SDW1A
pazopanib
7RN5DR86CK
Paclitaxel
P88XT4IS4D
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1239-1251Subventions
Organisme : Medical Research Council
ID : MR/J007986/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N020782/1
Pays : United Kingdom
Références
Gynecol Oncol. 2010 Dec;119(3):484-90
pubmed: 20870280
J Cereb Blood Flow Metab. 2016 Feb;36(2):326-39
pubmed: 26661202
Nat Med. 2001 Sep;7(9):987-9
pubmed: 11533692
J Magn Reson Imaging. 2002 Oct;16(4):407-22
pubmed: 12353256
J Cereb Blood Flow Metab. 1993 Jan;13(1):15-23
pubmed: 8417003
Br J Cancer. 2017 Aug 8;117(4):478-484
pubmed: 28683470
J Clin Oncol. 2013 Aug 20;31(24):3034-43
pubmed: 23857966
Br J Cancer. 2014 Nov 11;111(10):1909-16
pubmed: 25349968
Br J Cancer. 2014 Jan 7;110(1):26-33
pubmed: 24231947
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Invest New Drugs. 2003 May;21(2):169-81
pubmed: 12889738
Curr Probl Diagn Radiol. 2015 Sep-Oct;44(5):407-24
pubmed: 25890454
J Biol Chem. 2000 Jul 21;275(29):21785-8
pubmed: 10801897
Clin Cancer Res. 2016 Dec 1;22(23):5738-5746
pubmed: 27470967
J Clin Oncol. 2014 May 1;32(13):1302-8
pubmed: 24637997
J Nucl Med. 2007 Sep;48(9):1536-44
pubmed: 17704249
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6610-6
pubmed: 18006761
Nat Rev Clin Oncol. 2012 Feb 14;9(3):167-77
pubmed: 22330689
EJNMMI Res. 2014 Dec;4(1):30
pubmed: 26055935
JAMA Oncol. 2018 Sep 1;4(9):1299
pubmed: 29978183
Bioorg Med Chem Lett. 2006 Dec 15;16(24):6190-3
pubmed: 17000103
Bioconjug Chem. 2008 Apr;19(4):951-7
pubmed: 18341272
J Clin Oncol. 2011 Oct 1;29(28):3798-804
pubmed: 21859991
Am J Obstet Gynecol. 1997 Sep;177(3):541-7
pubmed: 9322621
Clin Cancer Res. 2006 Jul 1;12(13):3942-9
pubmed: 16818691
J Clin Oncol. 2017 Apr 10;35(11):1231-1239
pubmed: 28221861
Lancet Oncol. 2012 Jul;13(7):724-33
pubmed: 22608783
J Cereb Blood Flow Metab. 1985 Dec;5(4):584-90
pubmed: 4055928
Cancer Res. 2002 Nov 1;62(21):6146-51
pubmed: 12414640
Curr Probl Diagn Radiol. 2015 Sep-Oct;44(5):425-36
pubmed: 25863438
Cancer Res Treat. 2016 Oct;48(4):1210-1221
pubmed: 26987390
Br J Cancer. 2010 Oct 26;103(9):1407-14
pubmed: 20924372
J Nucl Med. 2014 Nov;55(11):1878-84
pubmed: 25278514
J Clin Oncol. 2014 Oct 20;32(30):3374-82
pubmed: 25225436
Science. 1999 Aug 13;285(5430):1028-32
pubmed: 10446041
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
N Engl J Med. 2011 Dec 29;365(26):2484-96
pubmed: 22204725
Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):1994-1999
pubmed: 28174262
JAMA Oncol. 2018 Feb 1;4(2):196-202
pubmed: 29242937
Int J Gynecol Cancer. 2004 Sep-Oct;14(5):815-23
pubmed: 15361189
J Clin Oncol. 2008 Oct 1;26(28):4572-8
pubmed: 18824708
Lancet Oncol. 2015 May;16(5):561-8
pubmed: 25882986
Angiogenesis. 2014 Oct;17(4):909-20
pubmed: 25012543
Cancer Res. 2011 Jul 1;71(13):4412-22
pubmed: 21571862
Science. 1994 Apr 22;264(5158):569-71
pubmed: 7512751
J Cereb Blood Flow Metab. 1990 Sep;10(5):740-7
pubmed: 2384545
J Nucl Med. 2011 Mar;52(3):424-30
pubmed: 21321268
J Cereb Blood Flow Metab. 1983 Mar;3(1):1-7
pubmed: 6822610
Cancer Res. 2010 Mar 15;70(6):2171-9
pubmed: 20215520
J Clin Oncol. 2012 Jun 10;30(17):2039-45
pubmed: 22529265
Lancet Oncol. 2018 Sep;19(9):1247-1258
pubmed: 30100379
Gynecol Oncol. 2009 Mar;112(3):469-74
pubmed: 19135712
Clin Cancer Res. 2009 Jun 15;15(12):4220-7
pubmed: 19509175
Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2186-97
pubmed: 21892622
Clin Cancer Res. 1999 Mar;5(3):587-91
pubmed: 10100710
Br J Cancer. 2015 Nov 3;113(9):1282-8
pubmed: 26461056
J Nucl Med. 2015 Dec;56(12):1855-61
pubmed: 26383153
ISRN Obstet Gynecol. 2012;2012:245756
pubmed: 22792477
Am J Pathol. 1995 Jul;147(1):33-41
pubmed: 7541612
J Nucl Med. 2008 Jun;49(6):879-86
pubmed: 18483090
J Natl Cancer Inst. 2000 Sep 20;92(18):1534-5
pubmed: 10995813
Science. 1995 Dec 1;270(5241):1500-2
pubmed: 7491498
Clin Cancer Res. 2011 Nov 1;17(21):6914-23
pubmed: 21831954
Bioconjug Chem. 2011 Dec 21;22(12):2415-22
pubmed: 22026940